Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019.

2.

Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. No abstract available.

3.

Street triage services in England: service models, national provision and the opinions of police.

Kirubarajan A, Puntis S, Perfect D, Tarbit M, Buckman M, Molodynski A.

BJPsych Bull. 2018 Dec;42(6):253-257. doi: 10.1192/bjb.2018.62. Epub 2018 Sep 17.

4.

Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery.

Segall MD, Beresford AP, Gola JM, Hawksley D, Tarbit MH.

Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):325-37. Review.

PMID:
16866617
5.

In silico prediction of ADME properties: are we making progress?

Beresford AP, Segall M, Tarbit MH.

Curr Opin Drug Discov Devel. 2004 Jan;7(1):36-42. Review.

PMID:
14982146
6.

The emerging importance of predictive ADME simulation in drug discovery.

Selick HE, Beresford AP, Tarbit MH.

Drug Discov Today. 2002 Jan 15;7(2):109-16.

PMID:
11790621
7.

Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries.

Lewis DF, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS.

Drug Metabol Drug Interact. 1999;15(1):1-49. Review.

PMID:
10707112
9.

Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.

Lewis DF, Lake BG, George SG, Dickins M, Eddershaw PJ, Tarbit MH, Beresford AP, Goldfarb PS, Guengerich FP.

Toxicology. 1999 Nov 29;139(1-2):53-79.

PMID:
10614688
11.

Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity.

Lewis DF, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS.

Toxicology. 1999 Mar 1;133(1):1-33.

PMID:
10413191
13.

A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro.

Ogg MS, Williams JM, Tarbit M, Goldfarb PS, Gray TJ, Gibson GG.

Xenobiotica. 1999 Mar;29(3):269-79.

PMID:
10219967
14.

Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate.

Lewis DF, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS.

Chem Biol Interact. 1998 Oct 2;115(3):175-99. Review. Erratum in: Chem Biol Interact 1999 Jan 29;117(2):187.

PMID:
9851289
15.
16.
17.

Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium.

Graham KA, Hoenich NA, Tarbit M, Ward MK, Goodship TH.

J Am Soc Nephrol. 1997 Apr;8(4):627-31.

18.
19.

Genetic analysis of the human cytochrome P450 CYP2C9 locus.

Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR.

Pharmacogenetics. 1996 Oct;6(5):429-39.

PMID:
8946475
20.
21.

The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.

Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH.

Drug Metab Dispos. 1996 May;24(5):555-9.

PMID:
8723736
22.

Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans.

Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH.

Drug Metab Dispos. 1995 Nov;23(11):1225-30.

PMID:
8591723
23.
24.

Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver.

Dixon CM, Park GR, Tarbit MH.

Biochem Pharmacol. 1994 Mar 29;47(7):1253-7.

PMID:
8161354
25.

Applications of molecular biology and in vitro technology to drug metabolism studies: an industrial perspective.

Tarbit MH, Bayliss MK, Herriott D, Hood SR, Hutson JL, Park GR, Serabjit-Singh CJ.

Biochem Soc Trans. 1993 Nov;21(4):1018-23. Review. No abstract available.

PMID:
8131890
26.

Disposition of salmeterol xinafoate in laboratory animals and humans.

Manchee GR, Barrow A, Kulkarni S, Palmer E, Oxford J, Colthup PV, Maconochie JG, Tarbit MH.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1022-8.

PMID:
7905380
27.

Disposition of sumatriptan in laboratory animals and humans.

Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH.

Drug Metab Dispos. 1993 Sep-Oct;21(5):761-9.

PMID:
7902233
28.
29.

The disposition and metabolism of [14C]fluconazole in humans.

Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH.

Drug Metab Dispos. 1991 Jul-Aug;19(4):764-7.

PMID:
1680653
30.

Characterization of a quaternary, N-glucuronide metabolite of the imidazole antifungal, tioconazole.

Macrae PV, Kirrs M, Pullen FS, Tarbit MH.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1100-2. No abstract available.

PMID:
1981520
31.

The effects of anesthesia and surgery on metabolic homeostasis in infancy and childhood.

Ward Platt MP, Tarbit MJ, Aynsley-Green A.

J Pediatr Surg. 1990 May;25(5):472-8.

PMID:
2191106
32.

Discovery of fluconazole, a novel antifungal agent.

Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ.

Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S267-71. Review.

PMID:
2184503
34.

Neural dysfunction during hypoglycaemia.

Koh TH, Aynsley-Green A, Tarbit M, Eyre JA.

Arch Dis Child. 1988 Nov;63(11):1353-8.

35.

Comparison of two azole antifungal drugs, ketoconazole, and fluconazole, as modifiers of rat hepatic monooxygenase activity.

Houston JB, Humphrey MJ, Matthew DE, Tarbit MH.

Biochem Pharmacol. 1988 Feb 1;37(3):401-8.

PMID:
2827686
36.

In vitro potency and in vivo activity of azoles.

Troke PF, Marriott MS, Richardson K, Tarbit MH.

Ann N Y Acad Sci. 1988;544:284-93. No abstract available.

PMID:
3063173
37.

Design and evaluation of a systemically active agent, fluconazole.

Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ.

Ann N Y Acad Sci. 1988;544:4-11. No abstract available.

PMID:
2850752
38.

Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine.

Wood PR, Tarbit MH.

J Chromatogr. 1986 Nov 28;383(1):179-86. No abstract available.

PMID:
3029152
39.

Treatment of cryptococcal meningitis in mice with fluconazole.

Palou de Fernandez E, Patino MM, Graybill JR, Tarbit MH.

J Antimicrob Chemother. 1986 Aug;18(2):261-70.

PMID:
3019986
40.

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Humphrey MJ, Jevons S, Tarbit MH.

Antimicrob Agents Chemother. 1985 Nov;28(5):648-53.

41.

Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Antifungal and pharmacologic properties.

Marriott MS, Baird JR, Brammer KW, Faulkner JK, Halliwell G, Jevons S, Tarbit MH.

Dermatologica. 1983;166 Suppl 1:1-7.

PMID:
6884559
42.

Tioconazole, a new broad-spectrum antifungal agent: preclinical studies related to vaginal candidiasis.

Marriott MS, Brammer KW, Faccini J, Faulkner JK, Jevons S, Monro AM, Nachbaur J, Perraud J, Tarbit MH.

Gynakol Rundsch. 1983;23 Suppl 1:1-11. No abstract available.

PMID:
6683696
43.

The pattern of intramural veins of the left ventricle of the human heart.

Farrer-Brown G, Tarbit MH.

Br Heart J. 1975 Jan;37(1):85-93.

44.

The vascular pattern of the left ventricle of normal hearts from East Africans in Uganda.

Farrer-Brown G, Tarbit MH.

Afr J Med Sci. 1973 Oct;4(4):419-33. No abstract available.

PMID:
4792057
45.
46.

Microvascular study of hearts with endomyocardial fibrosis.

Farrer-Brown G, Tarbit MH, Somers K, Hutt MS.

Br Heart J. 1972 Dec;34(12):1250-62. No abstract available.

47.

The microvasculature of heart valves in rheumatic heart disease.

Farrer-Brown G, Tarbit MH.

Am Heart J. 1972 Nov;84(5):610-9. No abstract available.

PMID:
4639734
48.

Heart valve involvement in endomyocardial fibrosis.

Farrer-Brown G, Tarbit MH.

Br Heart J. 1972 Oct;34(10):1062-71. No abstract available.

49.

What is the spectrum of endomyocardial fibrosis?

Farrer-Brown G, Tarbit MH.

Trop Geogr Med. 1972 Sep;24(3):208-18. No abstract available.

PMID:
4636093
50.

The vascularisation of rheumatic heart valves.

Farrer-Brown G, Tarbit MH.

J Pathol. 1972 Jan;106(1):Pi. No abstract available.

PMID:
5035749

Supplemental Content

Loading ...
Support Center